151
Methods:
Four SAPHO patients who had mandibular non-
suppurative osteomyelitis with skin and osteoarticular lesions
were included in the study. Medical history, surgical treatment,
laboratory tests and imaging data were collected. Treatments and
the effects were also recorded.
Findings:
All patients had teeth extraction history, then they
had surgical interventions and repeated recurrence of mandibu-
lar symptoms postoperation. Computed tomography scan showed
solid-type periosteal reaction, external bone resorption and
bone enlargement. Scintigraphy showed increased uptake in
mandible and sternoclavicular joint. After corticosteroids, TwHF
and minocycline were applied, erythrocyte sedimentation rate,
C-reactive protein and visual analogue scale score decreased
significantly. Remission of mandibular and skin symptoms was
achieved and the disease was long-term controlled in our follow-
up.
Conclusions:
Mandibular osteomyelitis of SAPHO syndrome
may be induced by dental extraction and root canal therapy.
Surgical treatment for mandibular lesion is not recommended.
Combination therapy regimen of corticosteroid, TwHF and
minocycline is effective.
http://dx.doi.org/10.1016/j.ijom.2017.02.520Evaluation of minor salivary gland biopsy in the diagnosis of
Sjögren’s syndrome
S. Wicheta
∗
, W. Faquin, M. August
Massachusetts General Hospital, Boston, MA, United States
Background:
Sjögren’s syndrome (SS) is one of the most
common autoimmune diseases. In addition to xerostomia and
xeropthalmia, patients often present with extraglandular mani-
festations making diagnosis difficult. The two leading diagnostic
classification systems both include positive minor salivary gland
biopsy (MSGB) as a major inclusion criteria
. 1 However, diagnosis
can be made without histopathology if other criteria are met.
Objective:
To evaluate the role of the MSGB in establishing a
firm diagnosis of SS in a cohort of referred patients.
Methods:
This is a retrospective review of patients referred to the
MGH Department of Oral and Maxillofacial Surgery to rule in/out
SS over five years. Inclusion criteria were: complete information
regarding presenting symptoms, reason for referral and findings
on MSGB. Incomplete records and referral for reasons other than
presumptive SS resulted in exclusion. A total of 87 patients were
identified. Both diagnostic systems were evaluated to determine
the role of MSGB in diagnosis.
Findings:
Of 87 MSGB performed, 17 (19.5%) were positive
based on the histologic criteria of Chisholm and Mason
. 2 In 14
cases, it was the positive MSGB that allowed for the defini-
tive diagnosis (82.3%). In three cases, other criteria allowed
diagnosis without the contribution of the MSGB (sensitiv-
ity of MSGB = 82.3%; specificity = 90.0%; positive predictive
value = 66.6%; negative predictive value = 95.4%)
Conclusion:
The MSGB is an important contributor to a diag-
nosis of SS. When serology was negative (anti-SSA/Ro and
anti-SSB/La), the MSGB was often the criteria that allowed the
diagnosis to be established.
Reference
Rasmussen, A., Ice, J. A., Li, H., Grundahl, K., Kelly, J. A., Radfar, L.,
et al. (2014). Comparison of the American-European Consensus Group
Sjogren’s syndrome classification criteria to newly proposed American
College of Rheumatology criteria in a large, carefully characterised sicca
cohort.
Ann Rheum Dis
,
73
, 31–38.
Gerli, R., Muscat, C., Giansanti, M., Daniel, M. G., Sciuto, M., Gabrielli,
A., et al. (1997). Quantitative assessment of salivary gland inflammatory
infiltration in primary Sjögren’s syndrome: its relationship to differ-
ent demographic, clinical and serological features of the disorder.
Br
J Rheumatol
,
36
, 969–975.
http://dx.doi.org/10.1016/j.ijom.2017.02.521The role of pentoxifylline on the medication-related
osteonecrosis of the jaw via expression of vascular
endothelial growth factor in a rat model
G.M. Yalcin-Ülker
∗
, A. Cumbul, G. Duygu-Capar, Ü. Uslu,
K. Sencift
Department of Oral and Maxillofacial Surgery, Okan University
Faculty of Dentistry, Istanbul, Turkey
Objectives:
Bisphosphonates (BPs) cause alterations in angio-
genesis and neovascularisation on bone and it might be one of
the factors causing medication-related osteonecrosis of the jaw
(MRONJ). It is presented that pamidronate and zoledronic acid
(ZA) therapy reduces vascular endothelial growth factor (VEGF)
levels in serum. The aim of this experimental study is to investigate
VEGF expression in the BP- and pentoxifylline (PTX)-affected
jaw bone.
Methods:
Female Sprague-Dawley rats (
n
= 33) received ZA for
8 weeks to create osteonecrosis model. The left mandibular sec-
ond molar teeth were extracted and the recovery period lasted 8
weeks before sacrifice. PTX was intraperitoneally administered
to prevent MRONJ. Tissue samples were fixed in 10% neutral
formaldehyde. Samples were decalcified in the Morse’s solution
for 4–5 weeks, dehydrated in alcohol series and embedded in
paraffin. VEGF immunoreactivities incorporated both intensity
and distribution of staining (H Score).
Results:
The VEGF expression was significantly higher in
the bone of ZA group compared to control (26
±
5.65 versus
3.40
±
1.51, respectively;
P
< 0.001). PTX treatment significantly
decreased the VEGF expression in ZA/PTX/PTX group as com-
pared to ZA/PTX (respectively 11.20
±
4.03 versus 18.60
±
2.88;
P
< 0.05). This is the first experimental study showing VEGF lev-
els in the BP-affected jaw. The results showed ZA is increasing
VEGF levels in the bone and this may have a negative effect on
bone healing. PTX is a strong vasodilator and are being used
for peripheral vascular diseases and microcirculatory disorders.
It reduces VEGF levels in the bone and it might prevent MRONJ
via optimising vascular effects of ZA.
http://dx.doi.org/10.1016/j.ijom.2017.02.522The role of ATF4 in M2-polarised macrophage infiltration of
infantile haemangioma
J.H. Zhao
Wuhan University, Wuhan, China
Background:
Previous studies have demonstrated the effects of
hypoxia in the distinctive progression of infantile haemangioma
(IH), the most common benign tumour in infancy. Meanwhile,
the activating transcription factor 4 (ATF4) mediated anti-stress




